Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

1.940
-0.190-8.92%
Volume:104.66M
Turnover:202.39M
Market Cap:7.75B
PE:10.47
High:2.125
Open:2.125
Low:1.875
Close:2.130
52wk High:3.940
52wk Low:1.730
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:2.98
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.185
ROE:4.14%
ROA:2.44%
PB:0.41
PE(LYR):10.47
PS:1.05

Loading ...

FTSE China 50 Index Rebalance Adds GigaDevice, Pony.ai and WeRide Enter Southbound Stock Connect

Stock News
·
Jun 04

Luye Pharma to Repurchase 2028 Convertible Bonds at 103.13% and Issue New US$180 Million 5.25% CBs Due 2031

Bulletin Express
·
Jun 04

Luye Pharma - Proposed Concurrent Repurchase of US$180 Mln 6.25 per Cent. Convertible Bonds Due 2028

THOMSON REUTERS
·
Jun 04

Luye Pharma to Repurchase US$180.00 million 2028 CBs and Launch New USD Convertible Issue

Bulletin Express
·
Jun 03

LUYE PHARMA Announces Concurrent Tender Offer for $180 Million 2028 Convertible Notes and Proposed New USD-Denominated Convertible Bond Issuance

Stock News
·
Jun 03

Luye Pharma plans USD-denominated convertible bond issue alongside repurchase of US$ 180 million 6.25% convertibles due 2028

Reuters
·
Jun 03

Luye Pharma Schedules 26 June 2026 AGM; Proposes Director Re-elections, 20% Issuance Mandate and 10% Share Buyback

Bulletin Express
·
May 29

Luye Pharma announces annual general meeting

Reuters
·
May 29

Shandong Boan Bio submits US FDA BLA for two denosumab biosimilars

Reuters
·
May 29

Shandong Boan Biotechnology announces annual shareholder meeting

Reuters
·
May 27

Shandong Boan Biotechnology launches share buyback program worth up to HK$ 200 million

Reuters
·
May 13

Luye Pharma Reports Stable Share Capital and No Equity Movements in April 2026

Bulletin Express
·
May 07

Luye Pharma Releases 2025 ESG Report: Governance Upgrades, Emissions Rise on Higher Steam Consumption

Bulletin Express
·
Apr 29

绿叶制药(02186)2025年年报:营收63.084亿元,净利同比增9.4%,深耕四大治疗领域

Bulletin Express
·
Apr 29

Shandong Boan Biotech publishes 2025 annual report

Reuters
·
Apr 29

Luye Pharma publishes 2025 annual report

Reuters
·
Apr 29

Shandong Boan Bio proposes H-share restricted share unit incentive scheme

Reuters
·
Apr 28

Shandong Boan says China CDE accepts Phase II trial application for BA1106-BA1104 combo in NSCLC

Reuters
·
Apr 26

Luye Pharma launches first U.S. pharmacokinetic study for dual-acting VMAT2/Sigma-1R candidate LY03015

Bulletin Express
·
Apr 20

LUYE PHARMA's Innovative Drug LY03015 Enrolls First Patient in US Pharmacokinetic Bridging Study

Stock News
·
Apr 20